Loading chat...
US SB832
Bill
AI Summary
-
Amends the Medicare Drug Price Negotiation Program to extend the eligibility timeline for small-molecule drugs from 7 years to 11 years after FDA approval, matching the timeline for biologic drugs
-
Maintains the existing 7-year threshold for small-molecule drugs only for initial price applicability years 2026 and 2027
-
Beginning in 2028 and all subsequent years, small-molecule drugs must be on the market at least 11 years before becoming eligible for price negotiation
-
Introduced by Senator Tillis (R-NC) with four Republican co-sponsors on March 4, 2025, and referred to the Senate Finance Committee
Legislative Description
EPIC Act of 2025 Ensuring Pathways to Innovative Cures Act of 2025
Health
Last Action
Read twice and referred to the Committee on Finance.
3/4/2025